View ValuationKDventures 将来の成長Future 基準チェック /06現在、 KDventuresの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karl Anders Harfstrand was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Swedenお知らせ • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.お知らせ • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights Offeringお知らせ • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights Offeringお知らせ • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.お知らせ • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026お知らせ • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.お知らせ • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Swedenお知らせ • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.お知らせ • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.お知らせ • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.お知らせ • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.お知らせ • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 72% per year for the foreseeable future. Revenue is less than US$1m (kr1.9m revenue, or US$184k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€36.7m market cap, or US$39.9m).Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€37.5m market cap, or US$40.5m).Recent Insider Transactions • Feb 28Chief Executive Officer recently bought €7.2k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly €0.14 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.お知らせ • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024New Risk • Nov 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 67% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 67% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$194k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.3m market cap, or US$41.8m).お知らせ • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offeringお知らせ • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 28Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 18Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.お知らせ • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.9%.お知らせ • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023お知らせ • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 8.1% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Apr 26Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion StudyKarolinska Development AB (publ) announced that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4%.Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 08Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 93,360,022 Price\Range: SEK 4 Security Name: Class A Shares Security Type: Common Stock Securities Offered: 1,052,163 Price\Range: SEK 4 Transaction Features: Rights Offeringお知らせ • Dec 14Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.Organon & Co. (NYSE:OGN) agreed to acquire Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others for approximately $950 million on November 11, 2021. Under the agreement, Organon & Co. shall make an initial payment of $75 million. In addition, there are conditional payments totaling $270 million linked to milestones in the development and registration processes for the company's drug candidates, and additional payments totaling $600 million linked to commercial milestones. The completion of the transaction is subject to review by competition authorities and other customary conditions. The transaction is expected to close in December 2021. Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others on December 11, 2021. The consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Moelis & Company acted as exclusive financial advisor to Forendo.お知らせ • Dec 02Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate SevuparinKarolinska Development AB (publ) announced that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition. The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 174% share price gain to €1.13, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 79% over the past three years.Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.お知らせ • Aug 13Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical ProgramKarolinska Development AB announced that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid malignancies. The issue means there will be a pause in the patient enrollment until the agency reverses the decision. Patients previously enrolled and showing positive clinical responses will continue to receive study treatment. Aprea Therapeutics was initially notified of a partial hold in the myeloid malignancy clinical program and shortly thereafter received notification from the FDA that a clinical hold had also been issued in the ongoing lymphoid malignancy study. The agency's decision is related to the safety and efficacy data presented in a recent Phase 3 study of eprenetapopt in TP53-mutaed myelodysplastic syndrome (MDS). Aprea Therapeutics intends to work in close dialogue with the FDA to clarify and address the agency's concerns in order to resume activity in the clinical trial program as soon as possible. Karolinska Development has an interest in Aprea Therapeutics through KDev Investment amounting to a total holding of 8.4% of the outstanding shares in Aprea Therapeutics.お知らせ • Jun 18Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.Karolinska Development AB (publ) (OM:KDEV) acquired 21% stake in Anacardio AB on June 17, 2021. The consideration received under the transaction is intended to cover costs for necessary activities prior to a planned major capital raising to finance the first part of the project's clinical development. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 21% stake in Anacardio AB on June 17, 2021.Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020).Reported Earnings • Mar 31Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (€19k worth at the time). A total of 5 executives have left over the last 12 months.お知らせ • Mar 03+ 1 more updateKarolinska Development AB Announces CFO ChangesKarolinska Development AB announced that Per Aniansson has been appointed as new CFO. He has extensive experience in investments, business development and financing of high-growth companies in the life science industry. Per Aniansson takes up the position on March 7 and will initially work part-time (50%) in the company. He replaces Fredrik Järrsten, who has chosen to move on to a leading position within another life science company. Per Anainsson (b. 1966), Master of Science in Engineering and MBA, has over 20 years of experience from the venture capital industry. He has also been CEO of two MedTech companies and CFO of a wind power company. Per has been responsible for a large number of significant investments, fund raisings and exits, and has participated in six IPOs. Fredrik Järrsten has been CFO of the company since 2017 and Deputy CEO since 2019. In September 2020, the announced that he wished to leave his role to move on to a senior position in another life science company. He has remained at the company's continued disposal during the notice period to ensure a smooth transition.お知らせ • Feb 27Karolinska Development Appoints Johan Dighed as Deputy CEOKarolinska Development AB announced that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel.お知らせ • Feb 20Karolinska Development AB (publ) Announces Management AppointmentsKarolinska Development AB (publ) held an Extraordinary General Meeting on February 19, 2021. At the Extraordinary General Meeting, it was resolved, in accordance with the Nomination Committee’s proposal, to elect Anna Lefevre Skjöldebrand and Ben Toogood as new directors, and to elect Björn Cochlovius as new chairman of the Board of Directors.Reported Earnings • Feb 12Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).Is New 90 Day High Low • Nov 19New 90-day low: €0.21The company is down 24% from its price of €0.27 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €0.23The company is down 13% from its price of €0.26 on 31 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.お知らせ • Jul 31Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. Karolinska Development AB (publ) has an option agreement to increase the ownership in Svenska Vaccinfabriken Produktion AB to a total of 25% within a defined period of time and at a predetermined price. Karolinska Development will be represented on the Svenska Vaccinfabriken Produktion AB Board of Directors. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、KDventures は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:2I9 - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262-214-24-24N/A12/31/20252-194-26-26N/A9/30/20252-136-27-27N/A6/30/20252-80-34-34N/A3/31/20252-23-28-28N/A12/31/20242-8-28-28N/A9/30/20242-29-26-26N/A6/30/20242-6-24-24N/A3/31/2024234-22-22N/A12/31/202325-25-25N/A9/30/2023217-26-26N/A6/30/20232-41-27-27N/A3/31/20232-87-27-27N/A12/31/20222-88-33-33N/A9/30/20222-118-31-31N/A6/30/20222-721010N/A3/31/202221661010N/A12/31/202121711717N/A9/30/202122764747N/A6/30/2021210822N/A3/31/20212-106-6-6N/A12/31/20203-207-33-33N/A9/30/2020335-19-19N/A6/30/20203190-41-41N/A3/31/20204195-36-36N/A12/31/20193303N/A-7N/A9/30/20194-11N/A-6N/A6/30/201948N/A18N/A3/31/2019332N/A19N/A12/31/2018331N/A13N/A9/30/2018348N/A-60N/A6/30/20183238N/A-56N/A3/31/20183185N/A-49N/A12/31/20172180N/A-31N/A9/30/20175125N/A-6N/A6/30/20175-87N/A3N/A3/31/20175-142N/A6N/A12/31/20165-217N/A-9N/A9/30/20162-315N/A-32N/A6/30/20162-325N/A-95N/A3/31/20163-904N/A-122N/A12/31/20153-1,055N/A-325N/A9/30/20154-980N/A-375N/A6/30/20155-1,072N/A-342N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 2I9の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 2I9の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 2I9の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 2I9の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 2I9の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 2I9の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:56終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KDventures AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Johan LöchenABG Sundal Collier SponsoredEspen JørgensenDNB CarnegieKlas PalinDNB Carnegie Commissioned Research1 その他のアナリストを表示
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karl Anders Harfstrand was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Sweden
お知らせ • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.
お知らせ • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights Offering
お知らせ • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights Offering
お知らせ • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.
お知らせ • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026
お知らせ • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.
お知らせ • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Sweden
お知らせ • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.
お知らせ • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.
Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.
お知らせ • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.
Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025
New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 72% per year for the foreseeable future. Revenue is less than US$1m (kr1.9m revenue, or US$184k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€36.7m market cap, or US$39.9m).
Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.
Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€37.5m market cap, or US$40.5m).
Recent Insider Transactions • Feb 28Chief Executive Officer recently bought €7.2k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly €0.14 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.
Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.
お知らせ • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024
New Risk • Nov 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 67% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 67% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$194k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.3m market cap, or US$41.8m).
お知らせ • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offering
お知らせ • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 28Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 18Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.
Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.9%.
お知らせ • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023
お知らせ • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 8.1% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Apr 26Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion StudyKarolinska Development AB (publ) announced that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4%.
Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 08Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 93,360,022 Price\Range: SEK 4 Security Name: Class A Shares Security Type: Common Stock Securities Offered: 1,052,163 Price\Range: SEK 4 Transaction Features: Rights Offering
お知らせ • Dec 14Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.Organon & Co. (NYSE:OGN) agreed to acquire Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others for approximately $950 million on November 11, 2021. Under the agreement, Organon & Co. shall make an initial payment of $75 million. In addition, there are conditional payments totaling $270 million linked to milestones in the development and registration processes for the company's drug candidates, and additional payments totaling $600 million linked to commercial milestones. The completion of the transaction is subject to review by competition authorities and other customary conditions. The transaction is expected to close in December 2021. Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others on December 11, 2021. The consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Moelis & Company acted as exclusive financial advisor to Forendo.
お知らせ • Dec 02Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate SevuparinKarolinska Development AB (publ) announced that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition. The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 174% share price gain to €1.13, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 79% over the past three years.
Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 13Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical ProgramKarolinska Development AB announced that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid malignancies. The issue means there will be a pause in the patient enrollment until the agency reverses the decision. Patients previously enrolled and showing positive clinical responses will continue to receive study treatment. Aprea Therapeutics was initially notified of a partial hold in the myeloid malignancy clinical program and shortly thereafter received notification from the FDA that a clinical hold had also been issued in the ongoing lymphoid malignancy study. The agency's decision is related to the safety and efficacy data presented in a recent Phase 3 study of eprenetapopt in TP53-mutaed myelodysplastic syndrome (MDS). Aprea Therapeutics intends to work in close dialogue with the FDA to clarify and address the agency's concerns in order to resume activity in the clinical trial program as soon as possible. Karolinska Development has an interest in Aprea Therapeutics through KDev Investment amounting to a total holding of 8.4% of the outstanding shares in Aprea Therapeutics.
お知らせ • Jun 18Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.Karolinska Development AB (publ) (OM:KDEV) acquired 21% stake in Anacardio AB on June 17, 2021. The consideration received under the transaction is intended to cover costs for necessary activities prior to a planned major capital raising to finance the first part of the project's clinical development. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 21% stake in Anacardio AB on June 17, 2021.
Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020).
Reported Earnings • Mar 31Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).
Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (€19k worth at the time). A total of 5 executives have left over the last 12 months.
お知らせ • Mar 03+ 1 more updateKarolinska Development AB Announces CFO ChangesKarolinska Development AB announced that Per Aniansson has been appointed as new CFO. He has extensive experience in investments, business development and financing of high-growth companies in the life science industry. Per Aniansson takes up the position on March 7 and will initially work part-time (50%) in the company. He replaces Fredrik Järrsten, who has chosen to move on to a leading position within another life science company. Per Anainsson (b. 1966), Master of Science in Engineering and MBA, has over 20 years of experience from the venture capital industry. He has also been CEO of two MedTech companies and CFO of a wind power company. Per has been responsible for a large number of significant investments, fund raisings and exits, and has participated in six IPOs. Fredrik Järrsten has been CFO of the company since 2017 and Deputy CEO since 2019. In September 2020, the announced that he wished to leave his role to move on to a senior position in another life science company. He has remained at the company's continued disposal during the notice period to ensure a smooth transition.
お知らせ • Feb 27Karolinska Development Appoints Johan Dighed as Deputy CEOKarolinska Development AB announced that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel.
お知らせ • Feb 20Karolinska Development AB (publ) Announces Management AppointmentsKarolinska Development AB (publ) held an Extraordinary General Meeting on February 19, 2021. At the Extraordinary General Meeting, it was resolved, in accordance with the Nomination Committee’s proposal, to elect Anna Lefevre Skjöldebrand and Ben Toogood as new directors, and to elect Björn Cochlovius as new chairman of the Board of Directors.
Reported Earnings • Feb 12Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).
Is New 90 Day High Low • Nov 19New 90-day low: €0.21The company is down 24% from its price of €0.27 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €0.23The company is down 13% from its price of €0.26 on 31 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
お知らせ • Jul 31Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. Karolinska Development AB (publ) has an option agreement to increase the ownership in Svenska Vaccinfabriken Produktion AB to a total of 25% within a defined period of time and at a predetermined price. Karolinska Development will be represented on the Svenska Vaccinfabriken Produktion AB Board of Directors. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020.